Acrobat Genomics, NanoString, and Illumina Accelerator Collaborate with Stanford Medicine to Discover New
Benzinga Acrobat Genomics, NanoString Technologies, Inc. NSTG, and the Illumina Accelerator announced today their collaboration with Stanford Medicine to discover new drug targets for gene editing-based therapeutics using GeoMx Digital Spatial Profiling (DSP) technology. This collaboration aims to improve treatment options for patients suffering from interstitial lung diseases, such as idiopathic pulmonary fibrosis.
NanoString's GeoMx DSP is a powerful spatial biology platform that enables researchers to uncover intricate interactions between cells and identify the driving signaling pathways in multicellular systems. By spatially profiling whole transcriptome and high-plex protein expression in tissue samples, it provides invaluable insights into the cellular microenvironment, revealing the complex interplay between different cell types and the molecular mechanisms that contribute to disease progression. Acrobat Genomics, an innovative startup within the Illumina Accelerator Program specializing in gene editing technologies, will join forces with NanoString to receive a GeoMx DSP Technology Access Program grant. The grant was facilitated by the Illumina Accelerator, which brings together innovative genomics start-up companies with NanoString to form valuable partnerships.
